

EMAGINE



KERATOCONUS

- Treatment is Costly
- Needs an Operating Theatre
- Limited access in developing countries



INFECTIOUS KERATITIS

- AMR (antimicrobial resistance), global challenge by 2050
- High costs of treatment




SOLUTION


- CXL at the Slit Lamp



HOW DOES IT WORK?



EMAGine AG



The future of Cross-Linking
CXL at the Slit Lamp: the C-Eye Device



KERATOCONUS


- Treatment is Costly
- Needs an Operating Theatre
- Limited access in developing countries





INFECTIOUS KERATITIS


- AMR (antimicrobial resistance), global challenge by 2050
- High costs of treatment



AMR, a global problem

How does AMR compare?

Major causes of death (annual figures)



Source: The Review on Antimicrobial Resistance

Infectious keratitis - “Silent epidemic” (WHO)



Developed countries



Antibiotic resistance



Mixed infections



High costs



Developing countries



6-8 Million new cases / year



205'000 ophthalmologists





SOLUTION

- CXL at the Slit Lamp



HOW DOES IT WORK?





MULTIPLE INTENSITIES


- **3**
 - **9**
 - **18**
 - **30**
- mW/cm²**

REAL-TIME FLUORESCENCE MEASUREMENT



OPTIMIZED IRRADIATION PROFILE

- **More intensity in the corneal periphery, to compensate for thickness increase.**





STERILE CAP


- **Sterile interface between device and corneal surface**



P
device and



Linking







fluores
de

UV de

light s







EMAGine AG



- Swiss Company
- Spin-off from University of Geneva
- Based on extensive laboratory and clinical research



- Team members: more than 50 peer-reviewed scientific publications on Cross-Linking



Our motto:

***"Science First,
Marketing Second"***

MU
INT


THE C



- **Swiss Company**
- **Spin-off from University of Geneva**
- **Based on extensive laboratory and clinical research**

EMAGINE

- **Team members: more than 50 peer-reviewed scientific publications on Cross-Linking**





Our motto:

***“Science First,
Marketing Second”***



KERATOCONUS

- Treatment is Costly
- Needs an Operating Theatre
- Limited access in developing countries



INFECTIOUS KERATITIS

- AMR (antimicrobial resistance), global challenge by 2050
- High costs of treatment




SOLUTION


- CXL at the Slit Lamp



HOW DOES IT WORK?



EMAGine AG



The future of Cross-Linking
CXL at the Slit Lamp: the C-Eye Device